A partnership was reached by Illumina and Bristol-Myers Squibb to create and commercialize companion diagnostics for the pharmaceutical company's pipeline of oncology drugs. A diagnostic version of Illumina's TruSight Oncology 500 that will run on the NextSeq 550Dx is expected to be developed by the companies.
Illumina enters companion Dx development partnership with BMS
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.